


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.16%
-0.88%
-3.96%
+11.82%
-6.48%
MLTX
MoonLake Immunotherapeuti
$16.35
Strengths

Earnings are forecast to grow
MLTX Price Performance
$13.95 (+17.20%)
$9.36 (+74.68%)
$55.89 (-70.75%)
$45.99 (-64.45%)
MLTX has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

MLTX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MLTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MLTX Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
MRK
110.95
-0.06%
SNY
47.47
-0.88%
LLY
1032.97
-3.76%
INSM
159.27
-2.56%
IFRX
1.00
-6.54%
MLTX
MoonLake Immunotherapeuti
16.35
-6.09%
FTV
Fortive
55.51
-0.45%
PX
P10 Inc.
10.61
+1.68%
TPH
TRI Pointe Group
35.50
+1.23%
TRIP
TripAdvisor
13.99
+1.52%
What is MLTX current stock price?
What are MLTX stock strengths?
What is MLTX Risk Level?
What is MLTX market cap and volume?
What is MLTX current Stock IQ?
Should I buy MLTX stock right now?
Is MLTX a Strong Buy right now?
What does a 'Strong Buy' rating mean for MLTX?
What does a 'Strong Sell' rating mean for MLTX?
What factors influence MLTX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.16%
-0.88%
-3.96%
+11.82%
-6.48%
MLTX
MoonLake Immunotherapeuti
Current Price
$16.35
MLTX Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow
Linked to MLTX
MRK
110.95
-0.06%
SNY
47.47
-0.88%
LLY
1032.97
-3.76%
INSM
159.27
-2.56%
IFRX
1.00
-6.54%
Recently Viewed
MLTX
MoonLake Immunotherapeuti
16.35
-6.09%
FTV
Fortive
55.51
-0.45%
PX
P10 Inc.
10.61
+1.68%
TPH
TRI Pointe Group
35.50
+1.23%
TRIP
TripAdvisor
13.99
+1.52%

MLTX Price Performance
$13.95 (+17.20%)
$9.36 (+74.68%)
$55.89 (-70.75%)
$45.99 (-64.45%)
MLTX Analysts Opinion
MLTX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MLTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MLTX Street Sentiment is extremely bullish and have positive views on the near-term outlook
MLTX has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
MLTX Latest Analysis
MoonLake cut to sell at Goldman Sachs on risks to lead assets approval.
Today
BTIG Upgrades MoonLake Immunotherapeutics (MLTX). Fintel reports that on January 9 2026 BTIG upgraded their outlook for MoonLake Immunotherapeutics (NasdaqCM:MLTX) from Neutral to Buy. Analyst Price Forecast Suggests 34.04% Upside
Fri Jan 9, 2026
MoonLake Options Trading: A Deep Dive into Market Sentiment. Financial giants have made a conspicuous ish move on MoonLake. Our analysis of options history for MoonLake (NASDAQ:) revealed 20 unusual trades.Delving into the details we found 50% of traders were ish while 30% showed bearish tendencies. Out of all the trades we spotted 2 were puts with a value of $68040 and 18 were calls valued at $814168.After evaluating the trading volumes and Open Interest it'.s evident that the major market
Fri Jan 9, 2026
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission.
Fri Jan 9, 2026
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials Stock Soars. ) on Thursday received United States Food and Drug Administration (FDA) feedback regarding the clinical evidence strategy for Sonelokimab (SLK) in (HS) based on the Type B meeting requested by MoonLake.SLK was associated with significant improvements across different key outcomes in over 1000 patients with HS enrolled in the MIRA VELA-1 .MIRA trial data demonstrated a 43% response with 120mg SLK and a 29 ppt delta vs p
Thu Jan 8, 2026
MoonLake Catapults On FDA Deal For Its Down-And-Out Skin Disease Drug. Shares of MoonLake Immunotherapeutics catapulted Thursday after potentially aligning with the FDA on a path forward for its skin disease drug.The post MoonLake Catapults On FDA Deal For Its Down-And-Out Skin Disease Drug appeared first on Investor'.s Business Daily.
Thu Jan 8, 2026
MoonLake surges as no additional studies are required for lead drug.
Thu Jan 8, 2026
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street.
Thu Jan 8, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MLTX Stock trends
MLTX Stock performance
MLTX Stock analysis
MLTX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.